

Double chance of survival

Effective pharmacological treatment for **STROKE** patients

Cerebrolysin in Patients With Acute Ischemic Stroke in Asia (Cerebrolysin Acute Stroke Treatment in Asia - CASTA) Heiss et al. Stroke (2012) 43:630-636

with Cerebrolysin




Reconnecting Neurons. Empowering for Life.

Significant higher survival rate in Cerebrolysin group

Patients treated with Cerebrolysin improve chances for complete recovery

- \rightarrow Patients can get out of bed earlier
- \rightarrow Lower rate of severe complications
- → Functional improvements



Significant lower mortality rate in Cerebrolysin group

- Significant reduced death rate in Cerebrolysin group with 10.5% vs. 20.2% in placebo group
- As of day 5 considerable differences in mortality rate
- At day 13 placebo group already reaches final mortality rate of Cerebrolysin group
- Nearly no death after day 13 with Cerebrolysin, but continuously increase of death rate in placebo group

I The second sec	Titel	Cerebrolysin in Patients With Acute Ischemic Stroke in Asia Results of a Double-Blind, Placebo-Controlled Randomized Trial
	Patients	529 Cerebrolysin group + 541 placebo group = 1070 patients in total Cerebrolysin group = Cerebrolysin + standard treatment Placebo group = Saline + standard treatment
	Treatment	Treatment started within 12 hours of stroke onset 30ml/day for 10 days Primary endpoint = Combined result of BI ¹ , mRS ² and NIHSS ³ evaluated in 1 global test

¹BI = Barthel Index ²mRS = modified Rankin Scale ³NIHSS = National Institutes of Health Stroke Scale

ABBREVIATED PRESCRIBING INFORMATION. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics.

Copyright © 2017 by EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria. All rights reserved. No part of this brochure may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher. Cerebrolysin is a registered trademark of EVER Neuro Pharma GmbH, 4866 Unterach, Austria